"Gilead's Stock Plummets on Disappointing Phase 3 Lung Cancer Study Results"
Gilead Sciences announced that its Phase 3 EVOKE-01 study evaluating Trodelvy did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer (NSCLC). Despite this, a numerical improvement in overall survival favoring Trodelvy was observed, particularly in patients non-responsive to last prior anti-PD-(L)1 therapy. Gilead plans to discuss the results with regulators and explore potential pathways to understand Trodelvy's role in these patients. The company remains confident in its broader lung cancer clinical development program and intends to present the data at an upcoming medical meeting. Trodelvy is the first approved Trop-2-directed antibody-drug conjugate for certain types of metastatic breast cancers and metastatic urothelial cancer, but its safety and efficacy for metastatic NSCLC have not been established.